Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Kalaris Therapeutics (NASDAQ:KLRS) from a sell rating to a hold rating in a research note published on Saturday,Wall Street Zen reports.

A number of other research firms have also recently issued reports on KLRS. Weiss Ratings cut Kalaris Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a research note on Wednesday, May 13th. TD Cowen started coverage on shares of Kalaris Therapeutics in a report on Monday, June 15th. They issued a “buy” rating for the company. Wedbush started coverage on shares of Kalaris Therapeutics in a research report on Thursday, May 14th. They set an “outperform” rating and a $17.00 price objective for the company. Finally, Citizens Jmp dropped their price objective on shares of Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Kalaris Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.75.

Kalaris Therapeutics Trading Down 1.0%

NASDAQ:KLRS opened at $3.90 on Friday. Kalaris Therapeutics has a 1 year low of $3.03 and a 1 year high of $11.88. The stock has a market cap of $92.86 million, a price-to-earnings ratio of -1.93 and a beta of 0.22. The stock has a 50-day moving average price of $4.13 and a two-hundred day moving average price of $5.60.

Kalaris Therapeutics (NASDAQ:KLRS) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. Sell-side analysts forecast that Kalaris Therapeutics will post -1.99 earnings per share for the current year.

Hedge Funds Weigh In On Kalaris Therapeutics

A number of large investors have recently bought and sold shares of the company. XTX Topco Ltd bought a new position in shares of Kalaris Therapeutics during the 2nd quarter worth approximately $65,000. Johnson Financial Group Inc. bought a new stake in shares of Kalaris Therapeutics in the third quarter worth $58,000. Bridgeway Capital Management LLC acquired a new position in Kalaris Therapeutics during the third quarter worth $130,000. Woodline Partners LP acquired a new position in Kalaris Therapeutics during the third quarter worth $1,394,000. Finally, WHI TRUST Co LLC bought a new position in Kalaris Therapeutics in the fourth quarter valued at $823,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.